anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Sequoia Pitch

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 43,093
Current window 24,451-24,480
Pages 1,437
Rows per page 30
Arc: Sequoia Pitchclear collectionreset all
18 30 60

Arc

24,451-24,480 of 43,093

filter-aware
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
03
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
04
The slide highlights significant growth in revenue and net income metrics year-over-year.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Problem1 hit
07
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
08
The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
09
Includes a disclaimer regarding the forward-looking nature of the expectations.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
12
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
13
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
14
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
15
The slide illustrates the escalation of doses for both SAD and MAD study arms.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
16
SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
17
Includes box plots for AUC and Cmax across dose levels (1, 3, 8, 15, 25, 50 mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
18
The diagram illustrates a 4-way cross-over design with 4 patients, each receiving a different sequence of placebo and three dose levels (1mg, 3mg, 8mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
19
The slide presents clinical trial baseline data for a very small sample size (N=4).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
20
The table displays n (%) for adverse events related to the study drug.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
21
Data represents NT1 patients; N=4 per dose; P-values indicate statistical significance vs placebo.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
22
The chart uses a split x-axis to show pre-dose baseline and post-dose results. The 8mg dose maintains maximum sleep latency (40 min) for the duration of the test.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
23
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
24
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
25
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
26
Includes specific line items for share-based compensation, depreciation, amortization, separation expense, tax effects, non-cash interest, and a Janssen arbitration award.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Financials1 hit
03
The slide outlines the core therapeutic strategy of Arbutus Biopharma.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
04
The slide uses a column-based layout to present key value propositions.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
05
Arbutus Biopharma | Investor Presentation Deck | 25 slidesArbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit